Catherine Prady

Adjuvant Docetaxel for Node-Positive Breast Cancer

Miguel Martín, Tadeusz Pieńkowski, John R. Mackey et al. · New England Journal of Medicine · 2005 · 952 citations · Full text

Medicine, Oncology, Pharmacology +13

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer

Daniel Rayson, Sasha Lupichuk, Kylea Potvin et al. · Breast Cancer Research and Treatment · 2016 · 60 citations

Medicine, Oncology, Pharmacology +17

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

379MO Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study

Peter Schmid, Piotr J. Wysocki, Y.H. Park et al. · Annals of Oncology · 2023 · 46 citations · Full text

Medicine, Oncology, Pharmacology +14